The DOI matches its Crossref record; 58 of the 59 references it cites were found in a registry or an index.
Oxidative Damage Is the Earliest Event in Alzheimer Disease
Open accessAbstract
Recently, we demonstrated a significant increase of an oxidized nucleoside derived from RNA, 8-hydroxyguanosine (8OHG), and an oxidized amino acid, nitrotyrosine in vulnerable neurons of patients with Alzheimer disease (AD). To determine whether oxidative damage is an early- or end-stage event in the process of neurodegeneration in AD, we investigated the relationship between neuronal 8OHG and nitrotyrosine and histological and clinical variables, i.e. amyloid-beta (A beta) plaques and neurofibrillary tangles (NFT), as well as duration of dementia and apolipoprotein E (ApoE) genotype. Our findings show that oxidative damage is quantitatively greatest early in the disease and reduces with disease progression. Surprisingly, we found that increases in A beta deposition are associated with decreased oxidative damage. These relationships are more significant in ApoE epsilon4 carriers. Moreover, neurons with NFT show a 40%-56% decrease in relative 8OHG levels compared with neurons free of NFT. Our observations indicate that increased oxidative damage is an early event in AD that decreases with disease progression and lesion formation. These findings suggest that AD is associated with compensatory changes that reduce damage from reactive oxygen.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Past and recent studies have demonstrated that oxidative damage is not only an early event in the pathogenesis of AD, occurring before the onset of clinical symptoms but also a factor contributing to the disease progression [17,18,19,20,21].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [19]
In the citing paper
“In the brains of individuals with AD and preclinical AD (i.e., evidence of Aβ and tau deposition in the brain without any clinical manifestation of the disease), as well as patients with MCI (a mild clinical impairment with no proof of underlying pathology with biomarkers), many oxidative damage products are measured, and numerous investigations have pointed to OS as a key and early player in the”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [19]
In the citing paper
“In the AD brain, mitochondria can be sources of ROS and also the target of OS, especially mitochondrial DNA (mtDNA) is susceptible to oxidative damage [19,53,63].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [19]
In the citing paper
“Oxidative damage to RNA in EC, hippocampus, subiculum, and temporal neocortex of subjects with AD has been described. The levels of 8-OHdG increase early before pathological changes occur, and this can explain that the selective vulnerability of neurons in the EC during AD may be related to the vulnerability of these particular neurons to oxidative damage [19].”
From Role of Oxidative Damage in Alzheimer’s Disease and Neurodegeneration: From Pathogenic Mechanisms to Biomarker Discovery (2021) · cites this paper as [19]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Theory and Practice of Histological Techniques
Bancroft, J. D., & Gamble, M. (1990) · Cited by 6,948
Mirra, S. S., Heyman, A., McKeel, D., Sumi, S. M., Crain, B. J., Brownlee, L. M., Vogel, F. S., Hughes, J. P., Belle, G. V., Berg, L., et al. (1991) · Neurology · doi:10.1212/wnl.41.4.479 · Cited by 4,961
Restriction isotyping of human apolipoprotein E by gene amplification and cleavage with HhaI.
Hixson, J., & Vernier, D. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)43176-1 · Cited by 2,933
Consortium to Establish a Registry for Alzheimer's Disease (CERAD)
Fillenbaum, G., & Heyman, A. (2002) · doi:10.1002/0470846410.ch42(iii · Cited by 2,859
Diagnosis of Alzheimer's Disease
Khachaturian, Z. S. (1985) · Archives of Neurology · doi:10.1001/archneur.1985.04060100083029 · Cited by 2,499
Hydrogen peroxide mediates amyloid β protein toxicity
Behl, C. (1994) · Cell · doi:10.1016/0092-8674(94)90131-7 · Cited by 2,074
Mitochondrial abnormalities in Alzheimer's disease
Hirai, K., Aliev, G., Nunomura, A., Fujioka, H., Russell, R. L., Atwood, C. S., Johnson, A. B., Kress, Y., Vinters, H. V., Tabaton, M., et al. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-09-03017.2001 · Cited by 1,367
Self-citationReiman, E. M., Caselli, R. J., Yun, L. S., Chen, K., Bandy, D., Minoshima, S., Thibodeau, S. N., & Osborne, D. (1996) · New England Journal of Medicine · doi:10.1056/nejm199603213341202 · Cited by 1,366
Strittmatter, W. J., Weisgraber, K. H., Huang, D. Y., Dong, L. M., Salvesen, G. S., Pericak-Vance, M., Schmechel, D., Saunders, A. M., Goldgaber, D., & Roses, A. D. (1993) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.90.17.8098 · Cited by 1,363
Excess brain protein oxidation and enzyme dysfunction in normal aging and in Alzheimer disease.
Smith, C. D., Carney, J. M., Starke-Reed, P. E., Oliver, C. N., Stadtman, E. R., Floyd, R. A., & Markesbery, W. R. (1991) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.88.23.10540 · Cited by 1,296
Research works printed but not linked: 2
- Smith, 1998, ApoE: Isoform specific antioxidant activity [abstract], Neurobiol Aging, 19, S222
- Nunomura, 2000, Increasing amyloid ß 42 deposition is associated with decreasing neuronal RNA oxidation in Down's syndrome and familial Alzheimer's disease [abstract], Brain pathol, 10, 783
Cited by
Sorted by citations
Items 1,001–1,005 of 1,005
Progress in the development of new drugs in Alzheimer's disease
Piau, A., Nourhashémi, F., Hein, C., Caillaud, C., & Vellas, B. (2011) · The Journal of nutrition, health and aging · doi:10.1007/s12603-011-0012-x · Cited by 32
Perez-Corredor, P., Vanderleest, T. E., Vacano, G. N., Sanchez, J. S., Villalba-Moreno, N. D., Marino, C., Krasemann, S., Mendivil-Perez, M. A., Aguillón, D., Jiménez-Del-Río, M., et al. (2024) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2024.1373568 · Cited by 28
Yadav, M. K., Singh, S. K., Singh, M., Mishra, S. S., Singh, A. K., Tripathi, J. S., & Tripathi, Y. B. (2019) · Open Access Macedonian Journal of Medical Sciences · doi:10.3889/oamjms.2019.247 · Cited by 26
Neurofilaments are the major neuronal target of hydroxynonenal-mediated protein cross-links
Perry, E. A., Castellani, R. J., Moreira, P. I., Nunomura, A., Lui, Q., Harris, P. L. R., Sayre, L. M., Szweda, P. A., Szweda, L. I., Zhu, X., et al. (2013) · Free Radical Research · doi:10.3109/10715762.2013.794265 · Cited by 16
Guo, Q., Wang, T., Qian, C., & Wang, X. (2024) · Small · doi:10.1002/smll.202403980 · Cited by 15
Metadata
- Authors
- Nunomura, A., Perry, G., Aliev, G., Hirai, K., Takeda, A., Balraj, E. K., Jones, P. K., Ghanbari, H., Wataya, T., Shimohama, S., Chiba, S., Atwood, C. S., Petersen, R. B., & Smith, M. A.
- Affiliations
- Asahikawa Medical University (JP)
- Case Western Reserve University (US)
- Takeda (Japan) (JP)
- Sensei Biotherapeutics (United States) (US)
- Kyoto University (JP)
- Corresponding author
- Nunomura, Akihiko
- ORCID
- Venue
- Journal of Neuropathology & Experimental Neurology
- Publisher
- Oxford University Press (OUP)
- Published
- 2001-08
- Volume
- 60
- Issue
- 8
- Pages
- 759-767
- ISSN
- 0022-3069 (ISSN-L)
- 1554-6578
- OpenAlex
- W1542215809
- Cited by
- 1,885
- References
- 59
- Citations by year
- 2026: 46 · 2025: 31 · 2024: 52 · 2023: 61 · 2022: 80 · 2021: 98 · 2020: 86 · 2019: 82 · 2018: 69 · 2017: 73 · 2016: 70 · 2015: 83 · 2014: 86 · 2013: 86 · 2012: 104
- FWCI
- 33.08
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Neuropathology & Experimental Neurology (publishedVersion)
- PubMed (publishedVersion)
- Asahikawa Medical University Collection and Research (Asahikawa Medical University) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion)
- Funders
- Alzheimer's Association
- National Institutes of Health (5r01ag009287-08, AG09287)
- Japan Society for the Promotion of Science (12670918)
- National Institute on Aging (AG-14249, R01AG014249, AG 09287)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Life Sciences › Neuroscience › Neurology › Neuroinflammation and Neurodegeneration Mechanisms
- Keywords
- Alzheimer's disease, oxidative damage, 8-hydroxyguanosine, nitrotyrosine, amyloid plaques, neurofibrillary tangles, APOE ε4, disease progression, neurodegeneration, reactive oxygen species, RNA oxidation
- MeSH terms
- Aged, Alzheimer Disease, Apolipoproteins E, Brain, Female, Genotype, Guanosine, Heterozygote, Humans, Male, Middle Aged, Neurons, Tyrosine, Amyloid beta-Peptides, Neurofibrillary Tangles, Oxidative Stress, Disease Progression, Plaque, Amyloid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
